Robert W. Baird Issues Positive Forecast for Neurogene (NASDAQ:NGNE) Stock Price

Neurogene (NASDAQ:NGNE) had its target price hoisted by Robert W. Baird from $54.00 to $72.00 in a report issued on Tuesday morning,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

Separately, HC Wainwright cut their price target on shares of Neurogene from $51.00 to $49.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $63.33.

Neurogene Stock Down 44.1 %

NASDAQ:NGNE opened at $40.00 on Tuesday. Neurogene has a 52 week low of $12.49 and a 52 week high of $74.49. The firm’s fifty day moving average is $46.77 and its 200-day moving average is $40.05.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of NGNE. Quest Partners LLC bought a new stake in Neurogene in the second quarter valued at $55,000. SG Americas Securities LLC bought a new stake in Neurogene in the 1st quarter valued at about $120,000. Rhumbline Advisers acquired a new position in Neurogene during the 2nd quarter worth approximately $491,000. Avoro Capital Advisors LLC bought a new position in Neurogene in the second quarter worth approximately $802,000. Finally, Bank of New York Mellon Corp bought a new position in Neurogene in the second quarter worth approximately $1,107,000. 52.37% of the stock is owned by institutional investors.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.